| Abstract: |
Ovarian cancer is known for its aggressive pathological features, including the capacity to undergo epithelial to mesenchymal transition, promoting angiogenesis, metastatic potential, chemoresistance, inhibiting apoptosis, immunosuppression and promoting stem-like features. Galectins, a family of glycan-binding proteins defined by a conserved carbohydrate recognition domain, can modulate many of these processes, enabling them to contribute to the pathology of ovarian cancer. Our goal herein was to review specific galectin members identified in the context of ovarian cancer, with emphasis on their association with clinical and pathological features, implied functions, diagnostic or prognostic potential and strategies being developed to disrupt their negative actions. © 2020 by the authors. Licensee MDPI, Basel, Switzerland. |
| Keywords: |
unclassified drug; overall survival; clinical feature; review; nonhuman; pathophysiology; antineoplastic agent; cancer diagnosis; protein function; protein localization; ovarian cancer; cell proliferation; biological marker; disease association; metastasis; apoptosis; ovary cancer; mitogen activated protein kinase p38; antineoplastic activity; drug mechanism; cancer cell; cell migration; innate immunity; ca 125 antigen; galectin; cell interaction; invasion; toll like receptor; immunocompetent cell; galectin 1; molecularly targeted therapy; galectin 3; epithelial mesenchymal transition; chemoresistance; tumor invasion; immune suppression; ecalectin; galectins; cancer prognosis; human; 3,4 dichlorophenyl 3 deoxy 3 [4(3,4,5 trifluorophenyl) 1h 1,2,3 triazol 1 yl] 1 thio a dextro galactopyranoside; galectin 7; galectin 8; gb 1107; gm ct 01; gm ct 02; otx 008; td 139
|
